218 401

Cited 0 times in

Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea

DC Field Value Language
dc.contributor.author김대준-
dc.contributor.author김하은-
dc.contributor.author문덕환-
dc.contributor.author박병조-
dc.contributor.author백효채-
dc.contributor.author심효섭-
dc.contributor.author양영호-
dc.contributor.author이성수-
dc.contributor.author이진구-
dc.contributor.author이창영-
dc.contributor.author조응혁-
dc.contributor.author차윤진-
dc.contributor.author우원기-
dc.date.accessioned2023-03-03T02:39:01Z-
dc.date.available2023-03-03T02:39:01Z-
dc.date.issued2022-12-
dc.identifier.issn1759-7706-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192869-
dc.description.abstractBackground: The prognosis of invasive mucinous adenocarcinoma (IMA) remains controversial and should be clarified by comparison with the International Association for the Study of Lung Cancer (IASLC) histologic grading system for invasive nonmucinous adenocarcinoma (INMA). Methods: This study included patients with IMA who underwent curative resection. Their clinicopathological outcomes were compared with those of patients with INMA. Propensity score matching was performed to compare the prognosis of IMA with IASLC grade 2 or 3. Kaplan-Meier survival curves and log-rank tests were used to analyze recurrence-free survival (RFS) and overall survival (OS). Results: The prognoses of IMA and IASLC grade 2 were similar in terms of RFS and OS. Although patients with IMA had better RFS than patients with IASLC grade 3, the OS was not significantly different. After propensity score matching, IMA demonstrated similar RFS to IASLC grade 2 but superior to IASLC grade 3; there was no difference in the OS compared with grades 2/3. Multivariate analysis revealed that tumor size (hazard ratio [HR] = 1.20, p = 0.028), lymphovascular invasion (HR = 127.5, p = 0.003), and maximum standardized uptake value (HR = 1.24, p = 0.005) were poor prognostic predictors for RFS. Patients with IMA demonstrated RFS similar to and significantly better than that of patients with IASLC grades 2 and 3, respectively. For OS, IMA prognosis was between that of IASLC grades 2 and 3. Conclusions: Since the prognosis of IMA among lung adenocarcinomas appears to be relatively worse, further clinical studies investigating IMA-specific treatment and follow-up plans are necessary to draw more inferences.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherWiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute-
dc.relation.isPartOfTHORACIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdenocarcinoma of Lung* / pathology-
dc.subject.MESHAdenocarcinoma of Lung* / surgery-
dc.subject.MESHAdenocarcinoma* / pathology-
dc.subject.MESHAdenocarcinoma, Mucinous* / surgery-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.titlePrognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic and Cardiovascular Surgery (흉부외과학교실)-
dc.contributor.googleauthorWongi Woo-
dc.contributor.googleauthorYoung Ho Yang-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorDuk Hwan Moon-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorArthur Cho-
dc.contributor.googleauthorBong Jun Kim-
dc.contributor.googleauthorHa Eun Kim-
dc.contributor.googleauthorByung Jo Park-
dc.contributor.googleauthorJin Gu Lee-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorHyo Chae Paik-
dc.contributor.googleauthorSungsoo Lee-
dc.contributor.googleauthorChang Young Lee-
dc.identifier.doi10.1111/1759-7714.14687-
dc.contributor.localIdA00368-
dc.contributor.localIdA06134-
dc.contributor.localIdA05708-
dc.contributor.localIdA06090-
dc.contributor.localIdA01846-
dc.contributor.localIdA02219-
dc.contributor.localIdA05762-
dc.contributor.localIdA02866-
dc.contributor.localIdA03225-
dc.contributor.localIdA03245-
dc.contributor.localIdA03887-
dc.contributor.localIdA04001-
dc.relation.journalcodeJ02725-
dc.identifier.eissn1759-7714-
dc.identifier.pmid36345148-
dc.subject.keywordclassification-
dc.subject.keywordlung adenocarcinoma-
dc.subject.keywordmucinous adenocarcinoma-
dc.subject.keywordpathologic subtype-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.affiliatedAuthor김대준-
dc.contributor.affiliatedAuthor김하은-
dc.contributor.affiliatedAuthor문덕환-
dc.contributor.affiliatedAuthor박병조-
dc.contributor.affiliatedAuthor백효채-
dc.contributor.affiliatedAuthor심효섭-
dc.contributor.affiliatedAuthor양영호-
dc.contributor.affiliatedAuthor이성수-
dc.contributor.affiliatedAuthor이진구-
dc.contributor.affiliatedAuthor이창영-
dc.contributor.affiliatedAuthor조응혁-
dc.contributor.affiliatedAuthor차윤진-
dc.citation.volume13-
dc.citation.number23-
dc.citation.startPage3310-
dc.citation.endPage3321-
dc.identifier.bibliographicCitationTHORACIC CANCER, Vol.13(23) : 3310-3321, 2022-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.